Resilient Biotics is developing breakthrough live biotherapeutics to combat complex respiratory infections.
Using proprietary discovery analytics, we identify and design novel microbiome products that prevent disease-causing pathogens from taking hold in the respiratory tract. Our approach provides a new solution to help reduce dependency on antibiotics, and slow the spread of antibiotic-resistant microorganisms.
The company is building a portfolio of novel microbiome products to address major respiratory diseases in both human and animal health. Resilient is headquartered in the USA and is venture-backed by both institutional and strategic investors.